AORT

Business Context and Reporting Period

Company: CryoLife, Inc. (Note: Request metadata listed "ARTIVION, INC." but the filing text identifies the registrant as CryoLife, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: CryoLife preserves and distributes human cardiac and vascular tissues and develops medical devices for cardiac and vascular transplant applications. Key products include CryoValve SG, CryoPatch SG, BioGlue Surgical Adhesive, BioFoam Surgical Matrix, PerClot, and HemoStase.

Key Financial Metrics

Revenue Composition (2010): Preservation Services (51%), Medical Devices (49%), Other (1%). BioGlue and BioFoam accounted for 41% of total revenues. HemoStase accounted for 8%.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 4% year-over-year, driven by a 6% increase in preservation services and a 4% increase in product revenues.
• Profitability Decline: Net income decreased 55% to $3.9 million. Operating income dropped 32% to $9.9 million.
• Significant One-Time Charges:
  • Acquired In-Process R&D: Expensed $3.5 million related to the acquisition of PerClot distribution rights from Starch Medical, Inc. (SMI).
  • Investment Impairment: Recorded a $3.6 million "other than temporary" impairment charge on its investment in Medafor, Inc. common stock.
  • Inventory Write-Down: Wrote down $1.6 million of HemoStase inventory following the termination of the distribution agreement with Medafor.
  • Legal Costs: Incurred approximately $1.4 million in legal fees related to litigation with Medafor.
• Product Mix Shift: BioGlue revenues declined slightly due to competitive pressures and foreign exchange impacts, while HemoStase revenues increased significantly in 2010 (though expected to cease in 2011).

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• HemoStase Discontinuation: Sales of HemoStase are expected to cease in late March 2011 following Medafor's termination of the exclusive distribution agreement. Management anticipates a material adverse impact on 2011 revenues and profitability.
• PerClot Transition: CryoLife expects to transition international customers to PerClot and file an Investigational Device Exemption (IDE) with the FDA in early 2011 to pursue U.S. approval. Significant costs ($5.0M–$6.0M) are anticipated for regulatory approval and manufacturing.
• BioGlue Japan: Received Shonin approval in Japan for aortic dissection repair; distribution expected to begin in the first half of 2011.
• Liquidity: The company generated record cash from operations ($20.8M) and maintains a strong current ratio of 5:1. However, the credit facility with GE Capital expires in March 2011, and the company is reviewing options for renewal or replacement.

Risks and Contingencies

• Medafor Litigation: CryoLife is engaged in significant litigation with Medafor regarding the wrongful termination of the distribution agreement. Medafor has filed counterclaims seeking approximately $1.3 million plus interest. Trial is not expected until 2012.
• Patent Disputes: A German court nullified CryoLife's main BioGlue patent; the company has appealed, but the outcome is uncertain and could allow competitors to market similar products in Germany.
• Regulatory Approvals: Future growth depends on FDA approval for PerClot (U.S.) and BioFoam (U.S. clinical trials ongoing). Failure to obtain approvals would materially impact future revenues.
• Liability Claims: The company has accrued $2.6 million for unreported tissue processing and product liability claims, with a potential exposure up to $4.7 million.

Investor Verification Checklist

• Medafor Litigation Status: Verify the progress of the lawsuit and counterclaims, as the outcome could result in significant damages or loss of future revenue streams.
• HemoStase Inventory Realization: Confirm the ability to sell the remaining $559,000 of HemoStase inventory before the March 2011 deadline to avoid further write-downs.
• PerClot Regulatory Timeline: Monitor the filing and status of the IDE application with the FDA, as U.S. commercialization is contingent on this approval.
• Credit Facility Renewal: Assess the terms and availability of the new credit facility required to replace the one expiring in March 2011.
• BioGlue Patent Appeal: Track the status of the appeal regarding the German BioGlue patent nullification to understand competitive risks in the European market.
• Deferred Preservation Costs: Review the balance of deferred preservation costs ($31.6M) and the company's ability to manage these costs relative to tissue shipment volumes.